📰 Complement Therapeutics News
Complement Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Complement Therapeutics. Real-time updates on events, politics, business and more.
May 28, 2024
Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board Exonate Ltd., a biotechnology company developing novel
May 28, 2024
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director. Rafiq brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.
May 28, 2024
EXONATE APPOINTS DR RAFIQ HASAN AS NON-EXECUTIVE DIRECTOR Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens
May 26, 2024
In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.
May 26, 2024
A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.
May 25, 2024
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
May 25, 2024
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
May 6, 2024
Innovate UK has awarded a grant of more than £1 million to a trio of organisations working together on ‘life-changing’ gene therapies.
April 5, 2024
According to DelveInsight’s analysis, the growth of the gene therapies market in ophthalmology is expected to be mainly driven by the increasing prevalence of eye disease, rise in awareness and access to treatment, increased adoption of enhanced genetic testing and robust pipeline activity for eye disease in the 7MM. LAS VEGAS, April 4, 2024 /PRNewswire/ […]
April 4, 2024
/PRNewswire/ -- DelveInsights Gene Therapies in Ophthalmology Market Insights report includes a comprehensive understanding of current treatment practices,...